Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Get our best content in your email.

You are already a member! Please enter your password to sign in.


Group Portfolio

A group portfolio has not been created.

T.PLI > Group's Default Discussion > Results Due ! View modes: 
  • Results Due !

    - |
    User avatar
    4 stars

    AEterna Zentaris (t.aez, aezs) was expecting to have results of its phase 3 clinical trial for colon cancer in Q1 2012. Well as of today, Mar.21,  there are only 10 days left in Q1 now. As the trial ends at 360 deaths, it could well mean that their cancer drug Perifosine is working very well. Good results here will have this stock flying as the phase 3 trial is the last one before an NDA (new drug application) can be applied to the FDA. This drug has blockbuster written all over it in my opinion as it is being tested along side a current blockbuster drug Xeloda that has projected sales of $3 billion annually. Thats $3,000,000,000 annually! The company also has a very deep pipeline of other potential  blockbuster drugs in development. But the key thing here is results are due and good results should send this stock flying!


    Rate this post
    0 stars



Latest Members


Group Administrator